Multiple Myeloma Research Foundation
10
0
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
30.0%
3 terminated/withdrawn out of 10 trials
62.5%
-24.0% vs industry average
0%
0 trials in Phase 3/4
80%
4 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
Role: collaborator
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
Role: collaborator
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Role: collaborator
MMRF Molecular Profiling Protocol
Role: lead
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
Role: collaborator
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Role: collaborator
MMRF CureCloud Research Initiative
Role: lead
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Role: lead
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Role: collaborator
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
Role: collaborator
All 10 trials loaded